In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gossamer Bio, Inc.

https://www.gossamerbio.com

Latest From Gossamer Bio, Inc.

Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis

The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.

Clinical Trials Business Strategies

Gossamer Hopes To Stand Out In Crowded Spaces

The company plans to release topline results this year in ulcerative colitis and pulmonary arterial hypertension. In UC, especially, Gossamer is aiming for an opportunity that remains untapped.

Inflammation Sales & Earnings

ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment. 

Financing Innovation

Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost

Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AA BioPharma Inc.
    • Adhaere Pharmaceuticals, Inc.
    • GB006, Inc.
    • Pulmagen Therapeutics LLP
UsernamePublicRestriction

Register